APOA2 and pancreatic neoplasm: This biomarker can distinguish patients with stage I/II of pancreatic cancer and its risk diseases from healthy subjects by detection of the cleaved pattern of the C-terminal ends of the amino acids of the apolipoprotein A2 (apoA2) homodimer [34–36].